Patents Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • Publication number: 20210277475
    Abstract: The present invention relates to methods of diagnosing traumatic brain injury (TBI) in a subject. The present invention also relates to methods of monitoring the progression of the TBI in a subject.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 9, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., University of Florida Research Foundation, Inc., Orlando Health, Inc., d/b/a Orlando Regional Medical Center
    Inventors: Radha K. MAHESHWARI, Nagaraja S. BALAKATHIRESAN, Manish BHOMIA, Kevin K. WANG, Linda PAPA
  • Patent number: 11090373
    Abstract: Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 17, 2021
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: David W. Scott, Yongchan Kim, Aihong Zhang
  • Patent number: 11085934
    Abstract: The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 10, 2021
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Harvey B. Pollard, Clifton L. Dalgard
  • Publication number: 20210238262
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 5, 2021
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce
  • Publication number: 20210230230
    Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.
    Type: Application
    Filed: January 29, 2021
    Publication date: July 29, 2021
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Christopher C. Broder, Katharine N. Bossart
  • Patent number: 11045462
    Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 29, 2021
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Maria F. Braga, Vassiliki Aroniadou-Anderjaska
  • Publication number: 20210188950
    Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
    Type: Application
    Filed: August 10, 2020
    Publication date: June 24, 2021
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Yee-Peng Chan, Christopher C. Broder
  • Publication number: 20210171610
    Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 2, 2019
    Publication date: June 10, 2021
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky
  • Patent number: 11007249
    Abstract: The present invention relates to methods of treating a subject suffering from or at risk of suffering from graft versus host disease (GvHD) comprising administering a therapeutically effective amount of at least one of pregnancy specific glycoprotein 1 (PSG1) or PSG9 to a subject in need thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 18, 2021
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gabriela Dveksler, Harry Malech
  • Patent number: 10987423
    Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 27, 2021
    Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
  • Patent number: 10968430
    Abstract: The present invention generally relates to the production of antigen-specific T regulatory cells (Tregs). Such cells can be used in therapy to minimize undesirable immune responses such as those observed in autoimmunity and hemophilia and other diseases as well as in the response to protein therapy for genetic diseases. Methods for producing antigen specific Tregs and conditions for preferential expansion of functionally stable, specific Tregs are also provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: April 6, 2021
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: David W. Scott, Yong Chan Kim
  • Patent number: 10967061
    Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 6, 2021
    Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
  • Publication number: 20210061875
    Abstract: Provided herein are compositions comprising engineered CD8+ T cells that express a heterologous T cell receptor (TCR) having specificity for an autoantigen bound to a Major Histocompatibility Complex (MHC) Class II. Also provided are methods for the treatment of an autoimmune disease comprising administering the engineered CD8+ T cells. Also provided are methods for generating engineered CD8+ T cells that express a heterologous MHC Class II TCR, including methods of isolating autoantigen-MHC class II specific TCR for use in engineering CD8+ T cells for treatment.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 4, 2021
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventor: Jason R. LEES
  • Patent number: 10900043
    Abstract: The present invention relates to compositions and methods for preventing and/or treating bacterial disease (e.g., disease caused by Neisseria sp. such as gonorrhea). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria sp. (e.g., Neisseria gonorrhoeae).
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: January 26, 2021
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Won Jong Kim, María Auxilio Rendón-Espinosa, Magdalene Yh So, Maira Goytia, Ann Jerse, Dustin Higashi
  • Publication number: 20210017540
    Abstract: Vectors and methods are disclosed for immortalizing mammalian cells by co-expression of v-raf and v-myc proteins. A replication-defective viral vector is used for improved safety. The vector comprises an optional marker gene, and is especially useful for producing an immortalized macrophage by a method that involves contacting the vector with a monocyte, proliferatively growing the monocyte, growing the monocytic cell on a solid surface, and then growing the monocytic cell on a porous surface. An immortalized macrophage is also disclosed.
    Type: Application
    Filed: March 19, 2019
    Publication date: January 21, 2021
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Brian C. Schaefer, Chelsi Beauregard
  • Patent number: 10842856
    Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 24, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: George E. Peoples, Sathibalan Ponniah
  • Patent number: 10821173
    Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: November 3, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: James J. Mond, Clifford M. Snapper, Xinle Cui
  • Patent number: 10799473
    Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: October 13, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Regina M Day, Ronald-Allan M Panganiban
  • Patent number: 10786683
    Abstract: Methods and devices related to wound healing using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: September 29, 2020
    Assignees: Nitto Denko Corporation, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Sazzadur Rahman Khan, Sheng Li, Amane Mochizuki, Xingjia Wu, Juanita Josephine Anders
  • Patent number: 10738104
    Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: August 11, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Yee-Peng Chan, Christopher C. Broder